fludarabine has been researched along with sirolimus in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (17.39) | 29.6817 |
2010's | 17 (73.91) | 24.3611 |
2020's | 2 (8.70) | 2.80 |
Authors | Studies |
---|---|
Claxton, DF; Ehmann, C; Rybka, W | 1 |
Liu, H; Sheng, ZY; Yao, YM; Yu, Y | 1 |
Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM | 1 |
Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ | 1 |
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
Berman, DM; Buchwald, P; Han, D; Kenyon, NM; Kenyon, NS; Rothen, D; Willman, M | 1 |
Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K | 1 |
Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S | 1 |
Bogusz, J; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P | 1 |
Banov, L; Calvillo, M; Dufour, C; Fioredda, F; Fischer, A; Gallicola, F; Miano, M; Micalizzi, C; Molinari, AC; Montobbio, G; Parasole, R; Petruzziello, F; Poggi, V; Svahn, J | 1 |
Baba, T; Hamanishi, J; Kang, HS; Kharma, B; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O | 1 |
Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M | 1 |
Bittencourt, H; Ceppi, F; Duval, M; Mallette, B; Ovetchkine, P; Teira, P; Therrien, R | 1 |
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C | 1 |
Treon, SP | 1 |
Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R | 1 |
Arroyo, DS; Bussi, C; Heller, V; Iribarren, P; Rodriguez, CM; Sastre, D; Slavutsky, I; Stanganelli, C | 1 |
Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC | 1 |
Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G | 1 |
1 review(s) available for fludarabine and sirolimus
Article | Year |
---|---|
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
6 trial(s) available for fludarabine and sirolimus
Article | Year |
---|---|
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine | 2015 |
16 other study(ies) available for fludarabine and sirolimus
Article | Year |
---|---|
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
[Effect of inhibitors of signal transducer and activator of transcription-1/3 on expression of tumor necrosis factor-alpha induced by high mobility group box-1 protein inflammatory response in rat peritoneal macrophages].
Topics: Animals; Cells, Cultured; Drug Interactions; HMGB1 Protein; Macrophages, Peritoneal; Male; Rats; Rats, Wistar; Signal Transduction; Sirolimus; STAT1 Transcription Factor; STAT3 Transcription Factor; Transcription, Genetic; Tumor Necrosis Factor-alpha; Vidarabine | 2006 |
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
Topics: Aged; Epstein-Barr Virus Infections; Everolimus; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Vidarabine | 2007 |
Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients.
Topics: Analgesics, Non-Narcotic; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Daclizumab; DNA, Viral; Ganciclovir; Humans; Immunoglobulin G; Immunosuppressive Agents; Islets of Langerhans Transplantation; Leukocytes; Macaca fascicularis; Organometallic Compounds; Organophosphorus Compounds; Retrospective Studies; Sirolimus; T-Lymphocytes; Tacrolimus; Transplantation, Homologous; Valganciclovir; Vidarabine | 2010 |
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2011 |
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Caspase 3; Caspase 9; Cladribine; Cyclophosphamide; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Rituximab; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vidarabine | 2013 |
Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance; Humans; Infant; Male; Red-Cell Aplasia, Pure; Sirolimus; Splenectomy; Treatment Outcome; Vidarabine | 2014 |
Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bayes Theorem; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Tumor Cells, Cultured; Vidarabine | 2013 |
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphopro
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Calcineurin; Child; Combined Modality Therapy; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Mycophenolic Acid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Disease Susceptibility; Female; Flow Cytometry; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Sirolimus; Treatment Outcome; Vidarabine | 2019 |
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2020 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |